Mimedx Group, INC.: management transactions · United States · SEC (Form 4)

About Mimedx Group, INC.

MIMEDX GROUP, INC. (Nasdaq: MDXG) is a U.S.-listed medical technology and biologics company trading on the NASDAQ market in the United States. Headquartered in Marietta, Georgia, the company has built its franchise around advanced healing solutions designed to support tissue repair, wound closure, and surgical recovery. Its core heritage is in placental biologics: human tissue allografts derived from donated birth tissue and processed through proprietary, patent-protected methods that are supported by a substantial body of scientific and clinical evidence. ([investors.mimedx.com](https://investors.mimedx.com/?utm_source=openai)) MIMEDX’s business today is centered on two main operating segments: wound care and surgical. In wound care, its products are used in the treatment of chronic and other hard-to-heal wounds, typically when conventional therapy is insufficient or a clinician decides an advanced biologic option is warranted. In surgical applications, the company’s portfolio is used across a range of specialties to support tissue healing and recovery. While placental biologics remain the company’s defining platform, MIMEDX broadened its offering in 2024 by adding animal-derived xenograft products, and in 2025 and early 2026 it entered into additional agreements with manufacturers and distributors to expand its wound and surgical menu further. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001376339/000137633926000011/mdxg-20251231.htm?utm_source=openai)) Founded in the early 2000s, MIMEDX evolved into a specialist in regenerative healing products with a strategy built on clinical data, intellectual property, and market access. The company highlights deep peer-reviewed evidence, real-world evidence, and a donor-supply network developed over many years with hospitals and clinician groups. Competitively, it operates in a highly regulated and fragmented market where reimbursement, physician adoption, clinical differentiation, and product breadth are critical to winning share. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001376339/000137633926000011/mdxg-20251231.htm?utm_source=openai)) Geographically, the company remains primarily U.S.-focused, and its products sold in the United States are regulated by the FDA. That said, management frames MIMEDX as a potential global provider of healing solutions, so the long-term opportunity is broader than the domestic market alone. For now, the United States is clearly the commercial center of gravity. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1376339/000137633926000035/a2025annual10-kxfinal.htm?utm_source=openai)) Recent developments have been notable. In February 2026, MIMEDX reported record fourth-quarter and full-year 2025 operating results, with full-year net sales up 20% and management guiding to 2026 sales of $340 million to $360 million. The board also authorized a $100 million share repurchase program through February 2028. In the first quarter of 2026, the company launched new organically developed products and signed an exclusive distribution agreement for additional surgical products, reinforcing a more diversified growth strategy. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1376339/000137633926000012/mdxg-q42025pressreleasev.htm?utm_source=openai))